Repeated intravenous ketamine benefits patients with treatment ‐resistant depression

Intravenous ketamine administered twice a week or three times a week resulted in sustained antidepressant effects compared with placebo in a group of patients with treatment‐resistant depression, a new study has found. Based on similar results between the two dosing frequencies, the researchers indicated that a twice‐weekly regimen could serve as an initial repeated‐dose strategy in this population.

Source: The Brown University Psychopharmacology Update - July 19, 2016 Category: Psychiatry Tags: What's New in Research Source Type: research